Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct; 68(10):1245-51.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Cardiovascular Physiological Phenomena
Cholesterol
Confidence Intervals
Diabetes Mellitus, Type 2
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ischemic Attack, Transient
Lipoproteins, HDL
Lipoproteins, LDL
Male
Metabolic Syndrome
Middle Aged
Proportional Hazards Models
Pyrroles
Retrospective Studies
Risk Factors
Stroke
Triglycerides
Young Adult

authors with profiles

Larry Goldstein